ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) EBIT

The latest EBIT for LSPRU is $-25B as of March 2026. That compares with $-4.4B in the prior-year period — down 458.0% year over year. That is below the sector sector average of $-69M. Investors often review this figure alongside ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, LSPRU's EBIT moved from $-4.4B to $-25B — a 458.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s operating scale or balance-sheet position.

Against its sector companies, LSPRU currently prints $-25B for EBIT, while the sector average sits near $-69M. That is roughly 35621.2% below the sector mean. Large gaps often invite a closer look at ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s growth, margins, and balance sheet.

A EBIT figure of $-25B for LSPRU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-69M. Explore the charts below for those layers of context.

After noting LSPRU's EBIT ($-25B), review year-over-year change from $-4.4B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.